

T-F Tsai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3112726/publications.pdf>

Version: 2024-02-01

249
papers

9,279
citations

70961

41
h-index

49773

87
g-index

251
all docs

251
docs citations

251
times ranked

7936
citing authors

#	ARTICLE	IF	CITATIONS
1	Secukinumab in Plaque Psoriasis – Results of Two Phase 3 Trials. <i>New England Journal of Medicine</i> , 2014, 371, 326-338.	13.9	1,675
2	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 400-409.	0.6	472
3	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2317-2327.	6.3	316
4	Tumor-Associated Macrophage-Induced Invasion and Angiogenesis of Human Basal Cell Carcinoma Cells by Cyclooxygenase-2 Induction. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1016-1025.	0.3	292
5	Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. <i>Journal of Dermatological Science</i> , 2011, 63, 40-46.	1.0	279
6	Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. <i>British Journal of Dermatology</i> , 2018, 178, 114-123.	1.4	269
7	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 83-98.e4.	0.6	264
8	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 60-69.e9.	0.6	258
9	Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. <i>New England Journal of Medicine</i> , 2019, 380, 981-983.	13.9	214
10	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 576-586.	6.3	198
11	Discrimination of basal cell carcinoma from normal dermal stroma by quantitative multiphoton imaging. <i>Optics Letters</i> , 2006, 31, 2756.	1.7	196
12	Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). <i>Journal of Dermatological Science</i> , 2011, 63, 154-163.	1.0	189
13	How irritant is water? An overview. <i>Contact Dermatitis</i> , 1999, 41, 311-314.	0.8	137
14	The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. <i>British Journal of Dermatology</i> , 2013, 169, 1295-1303.	1.4	123
15	A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 489-498.e3.	0.6	115
16	HLA-Cw6 and psoriasis. <i>British Journal of Dermatology</i> , 2018, 178, 854-862.	1.4	109
17	Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 277-294.	1.2	93
18	Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. <i>British Journal of Dermatology</i> , 2015, 173, 146-154.	1.4	87

#	ARTICLE	IF	CITATIONS
19	The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. <i>British Journal of Dermatology</i> , 2012, 167, 1145-1152.	1.4	83
20	Increased Risk of Chronic Kidney Disease in Rheumatoid Arthritis Associated with Cardiovascular Complications – A National Population-Based Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0136508.	1.1	83
21	Human leucocyte antigen-6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. <i>British Journal of Dermatology</i> , 2014, 171, 1181-1188.	1.4	78
22	Comparison of cutaneous tolerance and efficacy of calcitriol 3 ¹ g ointment and tacrolimus 0.3 ¹ g ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. <i>British Journal of Dermatology</i> , 2007, 157, 1005-1012.	1.4	73
23	Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients. <i>Archives of Dermatological Research</i> , 2016, 308, 55-63.	1.1	68
24	Inhibition of IL-17A by secukinumab shows no evidence of increased <i>Mycobacterium tuberculosis</i> infections. <i>Clinical and Translational Immunology</i> , 2017, 6, e152.	1.7	67
25	Cutaneous manifestations of Epstein-Barr virus-associated T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 1993, 29, 685-692.	0.6	66
26	Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and Asia. <i>International Journal of Infectious Diseases</i> , 2015, 34, 126-131.	1.5	63
27	Cutaneous angiocentric T-cell lymphoma associated with Epstein-Barr virus. <i>Journal of the American Academy of Dermatology</i> , 1992, 26, 31-38.	0.6	61
28	The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study. <i>Journal of Dermatological Science</i> , 2017, 88, 36-45.	1.0	61
29	Burden of atopic dermatitis in Asia. <i>Journal of Dermatology</i> , 2019, 46, 825-834.	0.6	61
30	The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). <i>Journal of Dermatological Treatment</i> , 2013, 24, 169-178.	1.1	59
31	Use of anti-tumor necrosis factor therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan. <i>Journal of Dermatology</i> , 2012, 39, 269-273.	0.6	55
32	Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. <i>Acta Dermato-Venereologica</i> , 2018, 98, 829-834.	0.6	55
33	Clinical experience of QuantiFERON-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.4	50
34	Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. <i>BMJ Open</i> , 2021, 11, e043666.	0.8	48
35	Study on the effects of nylon-chitosan-blended membranes on the spheroid-forming activity of human melanocytes. <i>Biomaterials</i> , 2006, 27, 5079-5088.	5.7	47
36	Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. <i>British Journal of Dermatology</i> , 2018, 179, 853-862.	1.4	47

#	ARTICLE	IF	CITATIONS
37	HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis. <i>British Journal of Dermatology</i> , 2012, 166, 288-297.	1.4	46
38	A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. <i>British Journal of Dermatology</i> , 2013, 168, 444-446.	1.4	46
39	Epstein-Barr Virus-Associated Intravascular Lymphomatosis within Kaposi's Sarcoma in an AIDS Patient. <i>American Journal of Surgical Pathology</i> , 1999, 23, 482-487.	2.1	46
40	T helper type 17 in psoriasis: From basic immunology to clinical practice. <i>Dermatologica Sinica</i> , 2012, 30, 136-141.	0.2	45
41	Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment. <i>Clinical Drug Investigation</i> , 2019, 39, 1195-1203.	1.1	44
42	Increased risk of arrhythmia in patients with psoriatic disease: A nationwide population-based matched cohort study. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 429-438.	0.6	43
43	The Phosphatidylinositol 3-Kinase/Akt Signal Pathway Is Involved in Interleukin-6-mediated Mcl-1 Upregulation and Anti-apoptosis Activity in Basal Cell Carcinoma Cells. <i>Journal of Investigative Dermatology</i> , 2002, 119, 1121-1127.	0.3	42
44	Contact leukomelanosis induced by the leaves of <i>Piper betle</i> L. (Piperaceae): A clinical and histopathologic survey. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, 583-589.	0.6	39
45	Allopurinol in Dermatology. <i>American Journal of Clinical Dermatology</i> , 2010, 11, 225-232.	3.3	39
46	Mapping of psoriasis to 17q terminus. <i>Journal of Medical Genetics</i> , 2005, 42, 152-158.	1.5	38
47	Unique Epitopes on $\text{CD}137$ in $\text{CD}4^+$ T Cell Receptors Are Potentially Applicable for Targeting IgE-Committed B Cells. <i>Journal of Immunology</i> , 2010, 184, 1748-1756.	0.4	38
48	Enhanced cell survival of melanocyte spheroids in serum starvation condition. <i>Biomaterials</i> , 2006, 27, 1462-1469.	5.7	37
49	Tenosynovitis Caused by <i>Mycobacterium arupense</i> in a Patient with Diabetes Mellitus. <i>Clinical Infectious Diseases</i> , 2008, 47, 861-863.	2.9	37
50	The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab. <i>PLoS ONE</i> , 2015, 10, e0142930.	1.1	36
51	Psoriasis in Taiwan: From epidemiology to new treatments. <i>Dermatologica Sinica</i> , 2018, 36, 115-123.	0.2	35
52	Epidemiology of psoriatic disease and current treatment patterns from 2003 to 2013: A nationwide, population-based observational study in Taiwan. <i>Journal of Dermatological Science</i> , 2016, 84, 340-345.	1.0	34
53	Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. <i>Rheumatology</i> , 2018, 57, 2001-2011.	0.9	34
54	Increased expression of the natural killer cell inhibitory receptor CD94/NKG2A and CD158b on circulating and lesional T cells in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2006, 155, 318-324.	1.4	33

#	ARTICLE	IF	CITATIONS
55	Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231984375.	1.1	33
56	Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 827-834.	0.6	33
57	Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. <i>Journal of Dermatological Treatment</i> , 2015, 26, 7-15.	1.1	32
58	Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment. <i>British Journal of Dermatology</i> , 2003, 148, 1060-1061.	1.4	31
59	Effects of glycolic acid on light-induced skin pigmentation in Asian and Caucasian subjects. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 238-243.	0.6	30
60	Multiple Epstein-Barr virus-associated subcutaneous angioleiomyomas in a patient with acquired immunodeficiency syndrome. <i>British Journal of Dermatology</i> , 2002, 147, 563-567.	1.4	30
61	Role of breast tumour kinase in the in vitro differentiation of HaCaT cells. <i>British Journal of Dermatology</i> , 2005, 153, 282-289.	1.4	30
62	Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: A case series. <i>Journal of Dermatology</i> , 2011, 38, 1096-1099.	0.6	30
63	Switching biologics in psoriasis - practical guidance and evidence to support. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 493-503.	1.3	30
64	Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. <i>British Journal of Dermatology</i> , 2018, 178, 1439-1440.	1.4	29
65	Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center. <i>Frontiers in Medicine</i> , 2021, 8, 812010.	1.2	29
66	Managing Scalp Psoriasis: An Evidence-Based Review. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 17-43.	3.3	28
67	HLA-Cw6 specificity and polymorphic residues are associated with susceptibility among Chinese psoriatics in Taiwan. <i>Archives of Dermatological Research</i> , 2002, 294, 214-220.	1.1	27
68	Taiwanese Dermatological Association consensus statement on management of psoriasis. <i>Dermatologica Sinica</i> , 2017, 35, 66-77.	0.2	27
69	Concomitant Sleep Disorders Significantly Increase the Risk of Cardiovascular Disease in Patients with Psoriasis. <i>PLoS ONE</i> , 2016, 11, e0146462.	1.1	27
70	HLA-DRB1*0701 and DRB1*1401 are associated with genetic susceptibility to psoriasis vulgaris in a Taiwanese population. <i>British Journal of Dermatology</i> , 1998, 139, 978-983.	1.4	26
71	Sweet syndrome with histiocytoid infiltrate and neutropenia: A rare combination. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 882-884.	0.6	26
72	Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from <sc>ERASURE</sc> phase <sc>III</sc> study. <i>Journal of Dermatology</i> , 2017, 44, 1129-1137.	0.6	26

#	ARTICLE	IF	CITATIONS
73	Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work. <i>Journal of Dermatology</i> , 2018, 45, 1353-1356.	0.6	26
74	Development of bullous pemphigoid during secukinumab treatment for psoriasis. <i>Journal of Dermatology</i> , 2017, 44, e220-e221.	0.6	25
75	Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 337-344.	0.6	25
76	Persistent Erythema Multiforme Treated with Thalidomide. <i>American Journal of Clinical Dermatology</i> , 2008, 9, 123-127.	3.3	24
77	Characteristics of skin and soft tissue infection caused by non-tuberculous mycobacteria in Taiwan. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 811-817.	0.6	24
78	Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab. <i>PLoS ONE</i> , 2017, 12, e0184178.	1.1	24
79	Epstein-Barr virus-associated lymphoproliferative disorder of granular lymphocytes presenting initially as cutaneous vasculitis. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 339-344.	0.6	23
80	Dapsone hypersensitivity syndrome in non-leprosy patients: A retrospective study of its incidence in a tertiary referral center in Taiwan. <i>Journal of Dermatological Treatment</i> , 2009, 20, 340-343.	1.1	23
81	Pityriasis rubra pilaris with polyarthritis treated with adalimumab. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 187-188.	0.6	23
82	Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis. <i>Acta Dermato-Venereologica</i> , 2015, 95, 711-716.	0.6	23
83	Interstitial granulomatous drug reaction presenting as erythroderma: remission after discontinuation of enalapril maleate. <i>British Journal of Dermatology</i> , 2008, 158, 1143-1145.	1.4	22
84	Recurrent Hyperglycemia During Adalimumab Treatment in a Patient With Psoriasis. <i>Archives of Dermatology</i> , 2008, 144, 1403-4.	1.7	22
85	Recommendations for a patient-centered approach to the assessment and treatment of scalp psoriasis: a consensus statement from the Asia Scalp Psoriasis Study Group. <i>Journal of Dermatological Treatment</i> , 2014, 25, 38-45.	1.1	22
86	Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1744-1749.	1.3	22
87	Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5518.	1.8	22
88	Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 345-352.	1.3	21
89	Topical use of systemic drugs in dermatology: A comprehensive review. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 1048.e1-1048.e22.	0.6	20
90	Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience. <i>Dermatology and Therapy</i> , 2019, 9, 553-569.	1.4	20

#	ARTICLE	IF	CITATIONS
91	Histopathologic-molecular Correlation in Early Mycosis Fungoides Using T-cell Receptor β Gene Rearrangement by Polymerase Chain Reaction with Laser Capture Microdissection. Journal of the Formosan Medical Association, 2007, 106, 265-272.	0.8	19
92	HLA-Cw1 and Psoriasis. American Journal of Clinical Dermatology, 2021, 22, 339-347.	3.3	19
93	Cytogenetic characterization of Epstein-Barr virus-associated T-cell malignancies. Cancer Genetics and Cytogenetics, 1993, 69, 25-30.	1.0	18
94	Quantitative Comparison of Skin Colors in Patients With ESRD Undergoing Different Dialysis Modalities. American Journal of Kidney Diseases, 2006, 48, 292-300.	2.1	18
95	Familial Mucinous Nevus. Pediatric Dermatology, 2008, 25, 288-289.	0.5	18
96	The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies. PLoS ONE, 2019, 14, e0225112.	1.1	18
97	A drug safety evaluation of risankizumab for psoriasis. Expert Opinion on Drug Safety, 2020, 19, 395-402.	1.0	18
98	Congenital cutaneous mucinosis with spontaneous regression: an atypical cutaneous mucinosis of infancy?. Clinical and Experimental Dermatology, 2009, 34, 804-807.	0.6	17
99	The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 991-998.	1.3	17
100	Herpes zoster-associated severity and duration of pain, health-related quality of life, and healthcare utilization in Taiwan: a prospective observational study. International Journal of Dermatology, 2015, 54, 529-536.	0.5	17
101	Health state utility, willingness to pay, and quality of life among Taiwanese patients with psoriasis. Dermatologica Sinica, 2016, 34, 185-191.	0.2	17
102	The role of β -blockers in dermatological treatment: a review. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 363-371.	1.3	17
103	Association between sleep disorders and subsequent chronic spontaneous urticaria development. Medicine (United States), 2018, 97, e11992.	0.4	17
104	Atrophic Pigmented Dermatofibrosarcoma Presenting as Infraorbital Hyperpigmentation. Dermatology, 1997, 194, 65-67.	0.9	16
105	Remission of Bullous Pemphigoid after Rituximab Treatment in a Psoriasis Patient on Regular Low-dose Methotrexate. Acta Dermato-Venereologica, 2014, 94, 108-109.	0.6	16
106	Taiwanese Dermatological Association consensus for the management of atopic dermatitis. Dermatologica Sinica, 2015, 33, 220-230.	0.2	16
107	Thymoma-associated multiorgan autoimmunity. BMJ Case Reports, 2019, 12, e229163.	0.2	16
108	Updates on the Treatment of Erythrodermic Psoriasis. Psoriasis: Targets and Therapy, 2021, Volume 11, 59-73.	1.2	16

#	ARTICLE	IF	CITATIONS
109	The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries. <i>Annals of Dermatology</i> , 2016, 28, 222.	0.3	15
110	Biologics switch in psoriasis. <i>Immunotherapy</i> , 2019, 11, 531-541.	1.0	15
111	Unilesional folliculotropic/syngotropic cutaneous T-cell lymphoma presenting as an indurated plaque on the nape. <i>International Journal of Dermatology</i> , 2006, 45, 1268-1270.	0.5	14
112	Recurrence of classical juvenile pityriasis rubra pilaris in adulthood: report of a case. <i>British Journal of Dermatology</i> , 2007, 157, 842-844.	1.4	14
113	Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers. <i>Dermatologica Sinica</i> , 2015, 33, 5-10.	0.2	14
114	Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1405-1409.	0.6	14
115	A review of antibiotics and psoriasis: induction, exacerbation, and amelioration. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 981-989.	1.3	14
116	Itraconazole in the Treatment of Nonfungal Cutaneous Diseases: A Review. <i>Dermatology and Therapy</i> , 2019, 9, 271-280.	1.4	14
117	Clinical characteristics, genetics, comorbidities and treatment of palmoplantar pustulosis: A retrospective analysis of 66 cases in a single center in Taiwan. <i>Journal of Dermatology</i> , 2020, 47, 1046-1049.	0.6	14
118	ABCB1 in dermatology: roles in skin diseases and their treatment. <i>Journal of Molecular Medicine</i> , 2021, 99, 1527-1538.	1.7	14
119	Severity of periodontitis and salivary interleukin-1 β are associated with psoriasis involvement. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1908-1916.	0.8	14
120	Fibroepithelial polyp of glans penis in a man who practiced genital hanging kung fu. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, S35-S37.	0.6	13
121	A Crusted Plaque on the Right Nipple. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 403.	3.8	13
122	Intralesional therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2013, 24, 340-347.	1.1	13
123	Psoriasis sparing the lower limb with postpoliomyelitis residual paralysis. <i>British Journal of Dermatology</i> , 2014, 171, 429-431.	1.4	13
124	Increased risk of aortic aneurysm (AA) in relation to the severity of psoriasis: A national population-based matched-cohort study. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 747-754.	0.6	13
125	Health-related quality of life among patients with moderate-to-severe plaque psoriasis in Taiwan. <i>Dermatologica Sinica</i> , 2018, 36, 190-195.	0.2	13
126	Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: An 8-year multicenter study. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 71-78.	0.6	13

#	ARTICLE	IF	CITATIONS
127	Recommendations for psoriatic arthritis management: A joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 926-938.	0.8	13
128	Capsaicin attenuates imiquimod-induced epidermal hyperplasia and cutaneous inflammation in a murine model of psoriasis. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111950.	2.5	13
129	Psoriasis and cardiovascular comorbidities with emphasis in Asia. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2012, 147, 189-202.	0.8	13
130	Genetic Analysis of CARD14 in Non-familial Pityriasis Rubra Pilaris: A Case Series. <i>Acta Dermato-Venereologica</i> , 2014, 94, 587-588.	0.6	12
131	Taiwanese Dermatological Association consensus for the definition, classification, diagnosis, and management of urticaria. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 968-980.	0.8	12
132	Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia. <i>Journal of Dermatology</i> , 2018, 45, 799-804.	0.6	12
133	Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study. <i>Journal of Dermatology</i> , 2019, 46, 752-758.	0.6	12
134	Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series. <i>British Journal of Dermatology</i> , 2019, 181, 1106-1107.	1.4	12
135	Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 211-232.	1.3	12
136	Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept. <i>Dermatologica Sinica</i> , 2013, 31, 11-18.	0.2	11
137	Recurrent Erythema Annulare Centrifugum During Ustekinumab Treatment in a Psoriatic Patient. <i>Acta Dermato-Venereologica</i> , 2013, 93, 208-209.	0.6	11
138	The economic burden of psoriatic diseases in Taiwan. <i>Journal of Dermatological Science</i> , 2014, 75, 183-189.	1.0	11
139	The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 224-226.	0.6	11
140	Psoriasis is associated with a greater risk for cardiovascular procedure and surgery in patients with hypertension: A nationwide cohort study. <i>Journal of Dermatology</i> , 2018, 45, 1381-1388.	0.6	11
141	Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 85-93.	1.6	11
142	Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 943-9.	0.4	11
143	A cystic teratoma of the skin. <i>Histopathology</i> , 1996, 29, 384-386.	1.6	10
144	Prevalence Status and Association With Human Papilloma Virus of Anal Squamous Proliferative Lesions in a Patient Sample in Taiwan. <i>Sexually Transmitted Diseases</i> , 2008, 35, 721-724.	0.8	10

#	ARTICLE	IF	CITATIONS
145	Polymorphisms of MTHFR gene associated with livedoid vasculopathy in Taiwanese population. <i>Journal of Dermatological Science</i> , 2009, 54, 214-216.	1.0	10
146	Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review. <i>Dermatologica Sinica</i> , 2012, 30, 51-56.	0.2	10
147	Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience. <i>Dermatologica Sinica</i> , 2017, 35, 25-29.	0.2	10
148	Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2094729.	1.2	10
149	Congenital Mucinous Eccrine Nevus in a 5â€Monthâ€Old Girl with Frequent Intertriginous Dermatitis. <i>Pediatric Dermatology</i> , 2008, 25, 573-574.	0.5	9
150	Correlation of thiopurine methyltransferase and inosine triphosphate pyrophosphatase polymorphisms and adverse effects induced by azathioprine treatment in Taiwanese dermatology patients. <i>Dermatologica Sinica</i> , 2014, 32, 13-18.	0.2	9
151	The Risk of Chronic Pancreatitis in Patients with Psoriasis: A Population-Based Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0160041.	1.1	9
152	Risk of fractures in vitiligo patients treated with phototherapyâ€”A retrospective population-based cohort study. <i>Journal of Dermatological Science</i> , 2016, 82, 197-203.	1.0	9
153	Increased risk of avascular necrosis in patients with psoriatic disease: A nationwide population-based matched cohort study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 903-910.e1.	0.6	9
154	Consistent responses with guselkumab treatment in Asian and nonâ€Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. <i>Journal of Dermatology</i> , 2019, 46, 1141-1152.	0.6	9
155	Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab. <i>Dermatology and Therapy</i> , 2021, 11, 301-306.	1.4	9
156	Minimal residual disease in hypopigmented mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, S198-S201.	0.6	8
157	Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderateâ€toâ€severe chronic plaque psoriasis in Taiwan: results of an openâ€label, singleâ€arm, multicentre pilot study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 923-930.	1.3	8
158	CK7+/CK20â€“ Merkel Cell Carcinoma Presenting as Inguinal Subcutaneous Nodules with Subsequent Epidermotropic Metastasis. <i>Acta Dermato-Venereologica</i> , 2010, 90, 438-439.	0.6	8
159	Genotype distribution of human papillomavirus in anogenital warts of male patients in Taiwan. <i>Dermatologica Sinica</i> , 2012, 30, 85-89.	0.2	8
160	Excimer light phototherapy of segmental and nonâ€segmental vitiligo: experience in Taiwan. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2012, 28, 6-11.	0.7	8
161	Tofacitinib in psoriatic arthritis. <i>Immunotherapy</i> , 2017, 9, 1153-1163.	1.0	8
162	Human leukocyte antigen and demographic characteristics in Chinese patients with active peripheral type psoriatic arthritis who had inadequate response to conventional disease-modifying antirheumatic drugs in a single dermatologic clinic. <i>PLoS ONE</i> , 2019, 14, e0210076.	1.1	8

#	ARTICLE	IF	CITATIONS
163	Pharmacological Management of Pediatric Pustular Psoriasis. <i>Paediatric Drugs</i> , 2020, 22, 265-277.	1.3	8
164	FUT8 Remodeling of EGFR Regulates Epidermal Keratinocyte Proliferation during Psoriasis Development. <i>Journal of Investigative Dermatology</i> , 2021, 141, 512-522.	0.3	8
165	Use of H-1 Antihistamine in Dermatology: More than Itch and Urticaria Control: A Systematic Review. <i>Dermatology and Therapy</i> , 2021, 11, 719-732.	1.4	8
166	Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab. <i>Dermatologica Sinica</i> , 2019, 37, 129.	0.2	8
167	Cutaneous Metaplastic Synovial Cyst: Unusual Presentation With "A Bag Of Worms". <i>Dermatologic Surgery</i> , 2003, 29, 198-200.	0.4	7
168	Congenital polypoid pigmented eccrine poroma of a young woman. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 366-368.	1.3	7
169	Skin Color is Associated with Insulin Resistance in Nondiabetic Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2009, 29, 458-464.	1.1	7
170	Relapsing polychondritis-like ear disease responding to etanercept in two patients with psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 1006-1007.	0.6	7
171	Etanercept use for psoriasis in Taiwan: a case series study. <i>International Journal of Dermatology</i> , 2013, 52, 673-680.	0.5	7
172	Preclinical evaluation of melanocyte transplantation by chitosan-based melanocyte spheroid patch to skin prepared by controlled sunburn blistering. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2018, 106, 2535-2543.	1.6	7
173	Risk of Psoriasis Following Terbinafine or Itraconazole Treatment for Onychomycosis: A Population-Based Case-Control Comparative Study. <i>Drug Safety</i> , 2018, 41, 285-295.	1.4	7
174	National trends in incidence, mortality, hospitalizations, and expenditures for pemphigus in Taiwan. <i>Journal of Dermatological Science</i> , 2020, 99, 203-208.	1.0	7
175	Predictive Value of NUDT15 Variants on Neutropenia Among Han Chinese Patients with Dermatologic Diseases: A Single-Center Observational Study. <i>Dermatology and Therapy</i> , 2020, 10, 263-271.	1.4	7
176	Long-term effectiveness and safety of ixekizumab in the treatment of 14 patients with a history of chronic erythrodermic psoriasis who failed prior secukinumab: A bicentric retrospective study. <i>Dermatologica Sinica</i> , 2021, 39, 87.	0.2	7
177	Subcutaneous panniculitis-like T-cell lymphoma presenting with clinicopathologic features of dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, e121-e123.	0.6	6
178	Keloidal Morphea. <i>New England Journal of Medicine</i> , 2011, 364, e28.	13.9	6
179	Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study. <i>Dermatology and Therapy</i> , 2022, 12, 511-527.	1.4	6
180	Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature. <i>Lupus</i> , 2022, 31, 891-894.	0.8	6

#	ARTICLE	IF	CITATIONS
181	Cutaneous myxoid fibroblastoma. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, S61-S64.	0.6	5
182	Granulomatous Slack Skin Presenting as Acquired Ichthyosis and Muscle Masses. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 29-32.	3.3	5
183	The Use of Biologics for Psoriasis in Asia-Pacific Region. <i>Current Rheumatology Reviews</i> , 2009, 5, 149-152.	0.4	5
184	Long-term control of refractory Schnitzler syndrome with anakinra: a case report. <i>Dermatologica Sinica</i> , 2010, 28, 82-86.	0.2	5
185	Kyrle's disease successfully treated with allopurinol. <i>International Journal of Dermatology</i> , 2011, 50, 1170-1172.	0.5	5
186	Transformation of myxofibrosarcoma into myxoinflammatory fibroblastic sarcoma. <i>Journal of Dermatology</i> , 2012, 39, 422-424.	0.6	5
187	The impact of long-term secukinumab treatment on Epstein-Barr virus and cytomegalovirus loads in patients with psoriasis. <i>International Journal of Dermatology</i> , 2016, 55, e600-e602.	0.5	5
188	Estimating the burden of genital warts in Taiwan. <i>Sexual Health</i> , 2017, 14, 485.	0.4	5
189	Juvenile-onset pustular psoriasis: case series and literature review. <i>British Journal of Dermatology</i> , 2020, 182, 816-817.	1.4	5
190	Use of calcium channel blockers in dermatology: a narrative review. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 481-489.	1.3	5
191	An Update of the Published Reports on Biologics Use for Psoriasis and the Reimbursement Status in Asia-Pacific Region. <i>Current Rheumatology Reviews</i> , 2012, 8, 227-234.	0.4	5
192	Taiwanese dermatological association consensus for the definition, classification, diagnosis, and management of urticaria: 2021 update. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1191-1203.	0.8	5
193	Elderly-onset generalized pustular psoriasis: a case series. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1567-1570.	0.6	5
194	Diffuse depigmentation in a patient with chronic myeloid leukemia. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 738-740.	0.6	4
195	Acantholytic dyskeratotic epidermal nevus. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2011, 77, 253.	0.2	4
196	Continuous, personalized healthcare integrated platform. , 2012, , .		4
197	Hepatitis B virus reactivation after ustekinumab treatment: reply from authors. <i>British Journal of Dermatology</i> , 2014, 170, 478-479.	1.4	4
198	Occurrence of psoriatic plaques on previous adalimumab injection sites during disease relapse in a patient with pustular psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e24-e26.	0.6	4

#	ARTICLE	IF	CITATIONS
199	Association between work time loss and quality of life in patients with Herpes Zoster: a pooled analysis of the MASTER studies. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 11.	1.0	4
200	Correlation of clinical diagnosis of dactylitis by the dermatologist and ultrasonographic diagnosis by the rheumatologist in patients with psoriasis arthritis: Experience of a single clinic. <i>Dermatologica Sinica</i> , 2021, 39, 27.	0.2	4
201	Sparing of injection sites in patients with extensive psoriasis treated with various biologics. <i>Dermatologica Sinica</i> , 2019, 37, 90.	0.2	4
202	Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review. <i>Dermatology and Therapy</i> , 2022, 12, 835-860.	1.4	4
203	Letters to the Editor. <i>Journal of Paediatrics and Child Health</i> , 2008, 44, 749-751.	0.4	3
204	Localized AL Amyloidosis in a Patient with Diffuse Large B-cell Lymphoma of the Breast. <i>Acta Dermato-Venereologica</i> , 2012, 92, 284-285.	0.6	3
205	Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field. <i>Clinical and Experimental Dermatology</i> , 2012, 37, 922-924.	0.6	3
206	Cutaneous Mycobacterium intracellulare infection presenting as multiple asymptomatic papulonodules in an immunocompetent adult: A case report and review of the literature. <i>Dermatologica Sinica</i> , 2013, 31, 82-85.	0.2	3
207	Neutrophilic sebaceous adenitis responsive to oral isotretinoin. <i>Dermatologica Sinica</i> , 2013, 31, 102-103.	0.2	3
208	Metastatic cellular fibrous histiocytoma. <i>Dermatologica Sinica</i> , 2016, 34, 102-105.	0.2	3
209	Prevalence, clinical features and treatment pattern of patients with concurrent diagnoses of rheumatoid arthritis and psoriatic disease: results of a 14-year retrospective study in a tertiary referral center. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231984790.	1.1	3
210	Response of superimposed linear psoriasis to ustekinumab: A case report. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2017, 83, 392.	0.2	3
211	The seroconversion rate of QuantiFERON-TB gold in-tube test in psoriatic patients receiving anti-interleukin-23 monoclonal antibodies. <i>Dermatologica Sinica</i> , 2022, 40, 94.	0.2	3
212	Comparison of the relative efficacy of different biologics in different body areas in patients with moderate to severe psoriasis receiving biologics and tofacitinib in phase 3 randomized controlled trials: a 15-year single-center experience. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 887-895.	1.3	3
213	Corticosteroid-induced Dercum's disease. <i>Dermatologica Sinica</i> , 2011, 29, 142-143.	0.2	2
214	A fatal case of cutaneous multicentric epithelioid angiosarcoma. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, e129-e131.	0.6	2
215	Mycosis fungoides with xanthomatization. <i>Dermatologica Sinica</i> , 2012, 30, 33-34.	0.2	2
216	Cutaneous irritancy of water. <i>Reviews on Environmental Health</i> , 2014, 29, 217-20.	1.1	2

#	ARTICLE	IF	CITATIONS
217	Adalimumab-induced lupus pernio-like eruption in a patient with psoriasis. <i>Dermatologica Sinica</i> , 2015, 33, 249-250.	0.2	2
218	Development of lichen striatus in a psoriasis patient treated with adalimumab. <i>Dermatologica Sinica</i> , 2015, 33, 41-42.	0.2	2
219	Image Gallery: Resolution of lichen striatus in a patient with coexisting chronic plaque psoriasis and vitiligo during secukinumab treatment. <i>British Journal of Dermatology</i> , 2017, 176, e96-e96.	1.4	2
220	Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review. <i>Clinical Drug Investigation</i> , 2020, 40, 915-926.	1.1	2
221	Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment. <i>British Journal of Dermatology</i> , 2020, 183, 7-8.	1.4	2
222	Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review. <i>Inflammation Research</i> , 2022, 71, 157-168.	1.6	2
223	Angiotensin converting enzyme and angiotensin converting enzyme inhibitors in dermatology: a narrative review. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 33-42.	1.3	2
224	Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00672.	0.6	2
225	Associations between HLA-Cw1 and Systemic Treatment Response of Asian Psoriasis Patients. <i>Molecular Diagnosis and Therapy</i> , 2022, 26, 541-549.	1.6	2
226	Exophytic Tumors on Ankles of a Patient with Psoriasis. <i>Clinical Infectious Diseases</i> , 2008, 46, 1067-1068.	2.9	1
227	Unilateral discoid lupus erythematosus at the site of a healed abrasion wound: an illustration of isotopic response. <i>Dermatologica Sinica</i> , 2011, 29, 75-76.	0.2	1
228	Multiple annular erythematous plaques on the back. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2011, 77, 727.	0.2	1
229	Multiple Discrete, Punched-out Ulcers in a Patient With Pemphigus Vulgaris. <i>Clinical Infectious Diseases</i> , 2011, 53, 396-398.	2.9	1
230	Herpes zoster duplex bilateralis symmetricus. <i>Dermatologica Sinica</i> , 2015, 33, 37-38.	0.2	1
231	An investigator-initiated, open-label, single-center, proof-of-concept-study of omalizumab in patients with poorly controlled acute urticaria. <i>Dermatologica Sinica</i> , 2017, 35, 161-162.	0.2	1
232	Risk of varicocele in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic disease: a population-based case-control study. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 411-413.	0.6	1
233	Ulcerative nodules on the perineum. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 355-356.	0.2	1
234	Psoriasis treated with adalimumab in a patient with common variable immune deficiency: A case report. <i>Dermatologica Sinica</i> , 2018, 36, 252-253.	0.2	1

#	ARTICLE	IF	CITATIONS
235	Botulinum toxin type A injection in the treatment of acquired symmetrical acrokeratoderma: One case report. <i>Dermatologic Therapy</i> , 2020, 33, e14442.	0.8	1
236	Secukinumab 2â€week vs. 4â€weekly dosing in plaqueâ€type psoriasis. <i>British Journal of Dermatology</i> , 2021, 184, 791-792.	1.4	1
237	Effects of risankizumab in patients with psoriasis previously treated with guselkumab: a case series. <i>European Journal of Dermatology</i> , 2021, 31, 251-252.	0.3	1
238	Basal cell carcinoma which developed on the surface of recurrent parotid pleomorphic adenoma: coincidence or causality?. <i>European Journal of Dermatology</i> , 2012, 22, 145-146.	0.3	1
239	Positive association of DRB1*0701, -*1401 and negative association of DQA1*0501 with psoriasis vulgaris. <i>Journal of Dermatological Science</i> , 1998, 16, S150.	1.0	0
240	THE EFFECT OF SERUM CONCENTRATION ON THE SPHEROID FORMING ACTIVITY AND CELL GROWTH OF HUMAN MELANOCYTES ON CHITOSAN SURFACE. <i>Biomedical Engineering - Applications, Basis and Communications</i> , 2006, 18, 42-46.	0.3	0
241	Pigmentation disorders in Taiwanese skin: a clinical experience. <i>International Journal of Cosmetic Science</i> , 2008, 27, 54-56.	1.2	0
242	Commentary on â€Chronic Idiopathic Urticaria in Taiwan: A Clinical Study of Demographics, Aggravating Factors, Laboratory Findings, Serum Autoreactivity and Treatment Responseâ€. <i>Journal of the Formosan Medical Association</i> , 2011, 110, 132-133.	0.8	0
243	A solitary facial tumor with erosion on an 81-year-old oriental woman. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2012, 78, 119.	0.2	0
244	Isolated erythematous plaque on the right cheek. <i>Dermatologica Sinica</i> , 2013, 31, 47-48.	0.2	0
245	Ulcerative nodules on the perineum. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2018, 109, 355-356.	0.2	0
246	Annular atrophic plaques on the penile shaft: An unusual location for Christianson disease?. <i>Australasian Journal of Dermatology</i> , 2020, 61, e455-e456.	0.4	0
247	Clinical validation and utility of Chinese Eppendorf Itch Questionnaire in adults with chronic pruritus symptoms. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 492-500.	0.8	0
248	Reply to Drs Brunasso and Massone about palmoplantar pustulosis and psoriasis. <i>Journal of Dermatology</i> , 2021, 48, e48.	0.6	0
249	Angiotensin II receptor blockers in dermatology: a narrative review. <i>Journal of Dermatological Treatment</i> , 0, , 1-5.	1.1	0